New analogues of fatty acids for the treatment of obesity, hypertension and fatty infiltration of the liver

 

The invention relates to medicine and applies to new analogues of fatty acids of General formula (1), pharmaceutical compositions for and methods of treating or preventing obesity, hypertension, fatty infiltration of the liver, multiple metabolic syndrome nutritional compositions and method of improving the quality of such products as meat, milk and eggs. 9 C. and 35 C.p. f-crystals, 8 ill., 10 table.

Description text in facsimile form (see graphic part).

Claims

1. Pharmaceutical composition for treatment and/or prevention of obesity, containing an effective amount of an analog of fatty acids of General formula (I)

where n is an integer from 1 to 12;

m is an integer from 0 to 23;

i is an odd number, and specifies the position relative COOR;

Xiindependently from each other selected from the group consisting of O, S, SO, SO2, Se and CH2;

R represents hydrogen or C1-C4alkyl,

provided that at least one of Xidoes not represent a CH2,

or its salt is the first song on p. 1, where Xi=3selected from the group consisting of O, S, SO, SO2and Se, and where Xi=5-25represents CH2.

4. The pharmaceutical composition according to p. 3, where Xi=3represents sulphur.

5. The pharmaceutical composition according to p. 3, where Xi=3represents selenium.

6. Pharmaceutical composition for treating and/or preventing hypertension, containing an effective amount of an analog of fatty acids of General formula (I)

where n is an integer from 1 to 12;

m is an integer from 0 to 23;

i is an odd number, and specifies the position relative COOR;

Xiindependently from each other selected from the group consisting of O, S, SO, SO2, Se and CH2;

R represents hydrogen or C1-C4alkyl,

provided that at least one of Xidoes not represent a CH2,

or its salts or prodrugs.

7. The pharmaceutical composition according to p. 6, where m is equal to or greater than 13.

8. The pharmaceutical composition according to p. 6, where Xi=3selected from the group consisting of O, S, SO, SO2and Se, and where Xi=5-25represents CH2.

9. The pharmaceutical composition according to p. 8, where Xi=3PR. Pharmaceutical composition for treatment and/or prevention of fatty infiltration of the liver, containing an effective amount of an analog of fatty acids of General formula (I)

where n is an integer from 1 to 12;

m is an integer from 0 to 23;

i is an odd number, and specifies the position relative COOR;

Xiindependently from each other selected from the group consisting of O, S, SO, SO2, Se and CH2;

R represents hydrogen or C1-C4alkyl,

provided that at least one of Xidoes not represent a CH2,

or its salts or prodrugs.

12. The pharmaceutical composition according to p. 11, where m is equal to or greater than 13.

13. The pharmaceutical composition according to p. 11, where Xi=3selected from the group consisting of O, S, SO, SO2and Se, and where Xi=5-25represents CH2.

14. The pharmaceutical composition according to p. 13, where Xi=3represents sulphur.

15. The pharmaceutical composition according to p. 13, where Xi=3represents selenium.

16. Pharmaceutical composition for treatment and/or prevention of multiple metabolic syndrome containing an effective amount of analou 1 to 12;

m is an integer from 0 to 23;

i is an odd number, and specifies the position relative COOR;

Xiindependently from each other selected from the group consisting of O, S, SO, SO2, Se and CH2;

R represents hydrogen or C1-C4alkyl,

provided that at least one of Xidoes not represent a CH2,

or its salts or prodrugs where multiple metabolic syndrome is marked with the term "metabolic syndrome", which, in particular, is characterized by hyperinsulinemia, insulin resistance, obesity, glucose intolerance, diabetes mellitus type 2, dyslipidemia and/or hypertension.

17. The pharmaceutical composition according to p. 16, where m is equal to or greater than 13.

18. The pharmaceutical composition according to p. 16, where Xi=3selected from the group consisting of O, S, SO, SO2and Se, and where Xi=5-25represents CH2.

19. The pharmaceutical composition according to p. 18, where Xi=3represents sulphur.

20. The pharmaceutical composition according to p. 18, where Xi=3represents selenium.

21. Similar fatty acids of General formula I

where n is an integer from 1 to 12;

m is positive COOR;

Xiindependently from each other selected from the group consisting of O, S, SO, SO2, Se and CH2;

R represents hydrogen or C1-C4alkyl,

provided that at least one of Xidoes not represent a CH2,

provided that if the formula contains only 1 Xithat does not represent a-CH2- Xi=3does not represent O, S, SO, SO2Se

or its salt or the prodrug.

22. A method of treating or preventing the condition of obesity or overweight, at which stage the introduction of the needy in this animal an effective amount of analogues of fatty acids of General formula (I)

where n is an integer from 1 to 12;

m is an integer from 0 to 23;

i is an odd number, and specifies the position relative COOR;

Xiindependently from each other selected from the group consisting of O, S, SO, SO2, Se and CH2;

R represents hydrogen or C1-C4alkyl,

provided that at least one of Xidoes not represent a CH2,

or their salts or prodrugs.

23. The method according to p. 22, where the specified vividly istvanne animal such as chickens, cows, sheep, goats or pigs.

25. The method according to p. 22, where the specified animal is a domestic animal such as a dog or cat.

26. The method according to p. 22, where the specified animal is a fish or crustaceans, such as salmon, cod, Tilapia, clams, oysters, lobsters or crabs.

27. The method according to p. 22, where m is equal to or greater than 13.

28. The method according to one of paragraphs.22-27, where Xi=3selected from the group consisting of O, S, SO, SO2and Se, and where Xi=5-25represents CH2.

29. The method according to p. 28, where Xi=3represents sulphur.

30. The method according to p. 28, where Xi=3represents selenium.

31. The method according to any of paragraphs.22-30, in which analogues of fatty acids administered in such a way that their therapeutically effective concentration essentially continuously supported in the blood of the animal during the period of their introduction.

32. The method according to any of paragraphs.22-31, where the composition of such analogs of fatty acids made in the form of a standard dosage forms.

33. Nutritional composition for reducing or preventing the increase in total body mass or total mass of body fat in animals, including humans, contain an effective amount analogues of fatty acids is dstanley an integer from 0 to 23;

i is an odd number, and specifies the position relative COOR;

Xiindependently from each other selected from the group consisting of O, S, SO, SO2, Se and CH2;

R represents hydrogen or C1-C4alkyl,

provided that at least one of Xidoes not represent a CH2,

provided that if the formula contains only 1 Xithat does not represent a-CH2- Xi=3does not represent O, S, SO, SO2Se

or their salts or prodrugs.

34. The way to reduce weight or reduce body fat mass in in need thereof of a human or animal in which it is administered an effective amount of a composition containing analogues of fatty acids of General formula (I)

where n is an integer from 1 to 12;

m is an integer from 0 to 23;

i is an odd number, and specifies the position relative COOR;

Xiindependently from each other selected from the group consisting of O, S, SO, SO2, Se and CH2;

R represents hydrogen or C1-C4alkyl,

provided that at least one of Xidoes not represent a CH2,

or the WMD from p. 34 or 35, where the animal is adapted to a small energy.

37. The method according to one of paragraphs.34-36, where m is equal to or greater than 13.

38. The method according to p. 36, where Xi=3selected from the group consisting of O, S, SO, SO2and Se, and where Xi=5-25represents CH2.

39. The method according to p. 38, where Xi=3represents sulphur.

40. The method according to p. 38, where Xi=3represents selenium.

41. The method according to p. 35 or 36, where the specified animal is a human.

42. How to change the distribution and fat content in animals to improve the quality of the meat or products such as milk and eggs in the diet of the animals add nutritional product containing analogues of fatty acids of the formula (I)

where n is an integer from 1 to 12;

m is an integer from 0 to 23;

i is an odd number, and specifies the position relative COOR;

Xiindependently from each other selected from the group consisting of O, S, SO, SO2, Se and CH2;

R represents hydrogen or C1-C4alkyl,

provided that at least one of Xidoes not represent a CH2,

or the salt or the prodrug.

43. The method according to p. 42, where the decree is I.

44. The method according to p. 42, where the specified animal is a fish or crustaceans, such as salmon, cod, Tilapia, clams, oysters, lobsters or crabs.

 

Same patents:

The invention relates to new compounds of the formula (I)

< / BR>
where AG represents a radical selected from formulas (a) and (b) below:

< / BR>
R1represents a halogen atom, -CH3CH2OR SIG7, -OR SIG7, СОR8, R2and R3taken together form a 5 - or 6-membered ring, R4and R5represent H, a halogen atom, a C1-C10-alkyl, R7represents H, R8represents H orX represents the radical-Y-C-, r' and r" is H, C1-C10alkyl, phenyl, Y represents S(O)nor SE, n = 0, 1, or 2, and salts of compounds of formula (I)

The invention relates to selenoorganicheskikh compounds, namely 1-methoxy-1-(2-chlorpheniramine)alkanal formula I

CH3-O-H-SEwhere R is methyl or isopropyl, exhibiting anti-inflammatory and antimicrobial activity

The invention relates to new biologically active compounds, specifically to hydrochloridum of aminosilanes aromatic series formula I

= CH-Se-Ar where R is methyl; R1is methyl or ethyl;

Ar - p-or-were, p-chlorophenyl or- naphthyl, showing a phosphate-protecting action

The invention relates to a method of producing foramerica diverticulae acid, which is used as a reagent in the synthesis of organofluorine

The invention relates to a compound having the formula

< / BR>
or its pharmaceutically acceptable salts, where R1represents tetrazolyl; R4, R5and R2each independently selected from hydrogen, alkyl, alkoxy, hydroxy, halogen, and so on, or aryl, possibly substituted CON(R9)2, NHCOR9, SO2N(R9)2, CO2R9where R9represents hydrogen, alkyl, cycloalkyl and t
The invention relates to medicine, specifically to a solid dosage form carvedilola made in the form of a solid dosage form containing carvedilol and pharmaceutically acceptable excipients, which are used starch, saccharide, stearic acid and/or its salt, having the stability during storage

Pharmaceutical drug // 2213577
The invention relates to medicine
The invention relates to medicine, more precisely to the pharmacy, and can be used for the preparation of solid pharmaceutical compositions, the active compound which is enalapril maleate
The invention relates to medicine, in particular to pharmaceutical drugs used in diseases of the cardiovascular system

The invention relates to the field of medicine and is suitable for the treatment of hypertension and congestive heart failure
The invention relates to medicine, specifically to pharmaceutical compositions comprising as active ingredient indapamide, and may find application in the treatment of hypertension and to prevent the delay of sodium and water in the body in chronic heart failure
The invention relates to medicine and can be used for the integrated treatment of edematic-fibrosclerotic panniculopathy (cellulite)

The invention relates to medicine and can be used in dentistry to prevent patients suffering from arterial hypertension and elevated risk factor in orthodontic treatment
The invention relates to the field of veterinary medicine

Antihypoxic tool // 2213571
Up!